Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07427394 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT07427394 is a Phase 2 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 24 participants.
The verdict
NCT07427394, a Phase 2 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.
Interventions
- DRUG Camizestrant
- DRUG Atirmociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2027-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07427394
The ClinicalTrials.gov registry entry for NCT07427394 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Camizestrant is the first listed.
NCT07427394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07427394 about?
NCT07427394 is a clinical study titled "Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer". A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.
What is the current status of trial NCT07427394?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2026-05-06. Estimated completion is 2027-12-03.
What interventions are being tested in trial NCT07427394?
The interventions under investigation include: Camizestrant (DRUG), Atirmociclib (DRUG).
Who is sponsoring clinical trial NCT07427394?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.